TrialHaematologica2024

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.

Linlin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.